This Article Abstract Full Text Full Text (PDF) View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (17) Citing Articles via Google Scholar Google Scholar Articles by Rodriguez, A. E. Search for Related Content PubMed PubMed Citation Articles by Rodriguez, A. E.

Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis

The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study

Alfredo E. Rodriguez, MD, PhD, FACC^_*,_*, Juan F. Granada, MD, Máximo Rodriguez-Alemparte, MD^_*, Cesar F. Vigo, MD^_*, Juan Delgado, MD^,1, Carlos Fernandez-Pereira, MD^_*, Antonio Pocovi, MD^_*, Alfredo M. Rodriguez-Granillo, BS^_*, Daryl Schulz, RTN, Albert E. Raizner, MD, FACC, Igor Palacios, MD, FACC, William O’Neill, MD, FACC, Grzegorz L. Kaluza, MD, PhD, Gregg Stone, MD, PhD, FACC^|| for the ORAR II Investigators

^_* Otamendi Hospital, Buenos Aires, Argentina
The Methodist Hospital Research Institute, Houston, Texas
Massachusetts General Hospital, Boston, Massachusetts
William Beaumont Hospital, Royal Oak, Michigan
^|| Columbia University, New York, New York Dr.

View larger version (13K): [in a new window]   Figure 1 Kaplan-Meier curves showing event-free survival from target lesion revascularization (A), target vessel revascularization (B), and major adverse cardiovascular events (C) for the global follow-up. The p values were calculated using the log-rank test.